Holen Sie sich die Stockscreener-App
23.54
1.68%
0.39
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$23.15
Offen:
$23.27
24-Stunden-Volumen:
1.05M
Relative Volume:
0.54
Marktkapitalisierung:
$1.60B
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-11.26
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
+4.58%
1M Leistung:
+12.52%
6M Leistung:
+40.29%
1J Leistung:
-36.98%
1-Tages-Spanne:
$22.99
$23.95
1-Wochen-Bereich:
$21.35
$23.95
52-Wochen-Spanne:
$9.98
$38.18
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Vergleichen Sie TNDM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
23.54 | 1.57B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
127.78 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.79 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
366.39 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.31 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.85 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Fortgesetzt | Stifel | Hold |
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
2026 world cup formations comparison: Will Tandem Diabetes Care Inc. stock benefit from infrastructure spending2026 world cup usa national team round of 16 goalkeepers low block defense winner prediction guide - Улправда
Positive changes ahead for diabetes in 2026 - BioWorld MedTech
The End of Shots? 5 Biotech Stocks Rethinking Diabetes - The Globe and Mail
Disposable Insulin Pumps Market is expected to reach US$ 6.9 - openPR.com
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors t - GuruFocus
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - PR Newswire
Tandem Diabetes Care Updates Bylaws, Tightens Governance Rules - TipRanks
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Favourable Signals For Tandem Diabetes Care: Numerous Insiders Acquired Stock - 富途牛牛
ROSEN, LEADING INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE - GlobeNewswire Inc.
HEDIS Glycemic Goal Achieved Using Control-IQ Technology - The American Journal of Managed Care® (AJMC®)
Is Tandem Diabetes Care (TNDM) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance
What Tandem Diabetes Care (TNDM)'s Canadian Smartphone Bolus Launch Means For Shareholders - Yahoo Finance
Tandem Diabetes Care (FRA:TD5A) EV-to-OCF : -179.84 (As of Dec. 25, 2025) - GuruFocus
Should Tandem’s Canadian Smartphone Bolus Launch Reshape How Investors View TNDM’s Connected-Care Strategy? - Sahm
Insulin Delivery Devices Market Outlook: Market to Reach US$ - openPR.com
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Artificial Pancreas System Market is set for steady growth to US$ - openPR.com
Price-Driven Insight from (TNDM) for Rule-Based Strategy - news.stocktradersdaily.com
Clinical ink announces collaboration with Tandem Diabetes Care to integrate Automated Insulin Delivery data into the GlucoseReady™ connected device software platform - PRWeb
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Gainers Report: Why Tandem Diabetes Care Inc. (TD5A) stock could break out in 2025Trade Risk Assessment & Verified Momentum Stock Watchlist - Улправда
Why Tandem Diabetes Care Inc. (TD5A) stock is a strong analyst pickQuarterly Trade Review & AI Enhanced Trading Alerts - Улправда
Will Tandem Diabetes Care Inc. (TD5A) stock beat value stocksJuly 2025 Snapshot & Fast Gain Stock Trading Tips - Улправда
Taking Stock of Tandem Diabetes Care (TNDM) After t:slim App Launch and Rising Growth Optimism - Sahm
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Book value per share of Tandem Diabetes Care, Inc. – SWB:TD5A - TradingView — Track All Markets
Stock Analysis: Will Tandem Diabetes Care Inc. stock split again soonWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - Улправда
How interest rate cuts could boost Tandem Diabetes Care Inc. stock2025 Breakouts & Breakdowns & Weekly High Return Forecasts - DonanımHaber
What risks investors should watch in Tandem Diabetes Care Inc. stockJuly 2025 Highlights & Reliable Breakout Stock Forecasts - Улправда
Is Tandem Diabetes Care Inc. stock oversold or undervaluedMarket Performance Recap & Community Verified Trade Signals - DonanımHaber
Q3 2025 Healthcare Technology Earnings Review: Revenue Beats & Stock PerformanceNews and Statistics - IndexBox
How resilient is Tandem Diabetes Care Inc. stock in market downturnsJuly 2025 Volume & Real-Time Market Sentiment Alerts - DonanımHaber
Will Tandem Diabetes Care Inc. stock deliver better than expected guidanceWeekly Investment Recap & Community Driven Trade Alerts - ulpravda.ru
Unpacking Q3 Earnings: Tandem Diabetes (NASDAQ:TNDM) In The Context Of Other Healthcare Technology Stocks - Yahoo Finance
What makes Tandem Diabetes Care Inc. (TD5A) stock appealing to growth investorsWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
TNDM Sees Analyst Rating Maintain and Price Target Rise by Truis - GuruFocus
Truist Securities Adjusts Price Target on Tandem Diabetes Care to $24 From $17, Maintains Hold Rating - marketscreener.com
Tandem t:slim Mobile App Now Available in Canada - Business Wire
Bank Watch: Will Tandem Diabetes Care Inc. (TD5A) stock beat value stocksQuarterly Portfolio Summary & Accurate Trade Setup Notifications - Улправда
The Bull Case For Tandem Diabetes Care (TNDM) Could Change Following Mobi-T Pump And App MilestonesLearn Why - Sahm
Mizuho Maintains Tandem Diabetes Care (TNDM) Neutral Recommendation - Nasdaq
Tandem Diabetes (TNDM) EVP reports RSU vesting and updated holdings - Stock Titan
RBC Adjusts Price Target on Tandem Diabetes Care to $30 From $25, Maintains Outperform Rating - marketscreener.com
TNDM: Mizuho Raises Price Target for Tandem Diabetes Care | TNDM Stock News - GuruFocus
Baird upgrades Tandem Diabetes Care stock rating to Outperform on Mobi-T launch - Investing.com Canada
Tandem Diabetes Care Shares Rise After Baird Upgrade - marketscreener.com
Tandem Diabetes (TNDM) Upgraded by Baird Amid MedTech Sector Out - GuruFocus
Tandem upgraded, Zimmer, ResMed downgraded at Baird (TNDM) - Seeking Alpha
Baird Upgrades Tandem Diabetes Care to Outperform From Neutral, Adjusts PT to $30 From $18 - marketscreener.com
TNDM Stock Sees 66.67% Price Target Increase with Outperform Rat - GuruFocus
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):